How To Make The Most Of Your GGB Awards Entries

Five Tips On How To Stand Out From The Crowd At This Year’s Event

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

The GGB Awards 2025 will take place on 29 October in Frankfurt (Shutterstock)

With the Global Generics & Biosimilars Awards 2025 returning to Germany in its twelfth year – for an awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries – entrants are already working on their submissions.

Every year, we receive enquiries from entrants asking how to make the most of their entries and stand out from the crowd in what is always a competitive field.

The five key tips below are designed to help companies entering the Global Generics & Biosimilars Awards 2025 to enhance their submissions and capture the attention of our judges.

  1. Be clear about your achievements: spell out upfront exactly why you think you should win the award, and what your achievement entails. Don’t be modest about highlighting successes!
  2. Tailor your entries to each category: while we always welcome entries from companies across multiple categories, it is always helpful to consider exactly why your achievement deserves to win in each specific category. Making sure that each specific entry is tailored to the category in question will ensure that the achievements are relevant for that particular prize.
  3. Be clear and concise: although we encourage entrants to give a full account of their achievements, the longest entries are not always the most successful! Being able to boil down your entry to the essential elements is important to capture the attention of judges who will be considering several entries in each category. Don’t be afraid of being bold and direct, and using plain language to be clear on exactly why you think you deserve to win. And if you want our judges to consider further resources, feel free to provide hyperlinks to additional content within the entry.
  4. Provide evidence of success: providing tangible evidence to demonstrate why your achievements were meaningful is a key element of each entry. Whether these details are financial or based on other metrics or feedback, it is always helpful to be able to provide a clear sense of the value of your achievements – both within and outside of your company.
  5. Stand out from the competition: in each category, entrants will be competing against multiple rivals, so it is important to ensure that your entry is something special that stands out against the rest of the pack. Aspects that are groundbreaking or have wider market relevance are a great way to show that you are an industry leader!

Entries for the Global Generics & Biosimilars Awards 2025 are now open and you can also book tickets to attend the awards ceremony, both of which are free of charge. The event will take place at the Radisson Blu Hotel, Frankfurt, on Wednesday 29 October, during CPhI Worldwide week.

Entries are open until Friday 1 August and can cover any activities undertaken between 1 August 2024 and 31 July 2025.

As in previous years, our 14 categories include:

  • Company of the Year
  • Regional Companies of the Year – Americas, APAC and EMEA
  • Acquisition of the Year
  • Leader of the Year
  • Value Added Medicine Initiative of the Year
  • Business Development of the Year
  • API Supplier of the Year
  • Biosimilar Initiative of the Year
  • Regulatory Achievement of the Year
  • Corporate Social Responsibility (CSR) Initiative of the Year
  • Industry Partner of the Year
  • Campaign of the Year

Adalvo is sponsoring the API Supplier of the Year award, while Parsity Group is sponsoring the Biosimilar Initiative of the Year category and Pharmacloud is once again sponsoring our Leader of the Year award. Our CSR Initiative of the Year award will once again be supported by longtime associate International Health Partners.

The Global Generics & Biosimilars Awards prides itself on its independence, with winners chosen solely on merit and acknowledged as the most deserving of recognition for their unique achievements.

All submissions are reviewed by an independent panel of expert judges, who have been selected on the basis of their industry knowledge and impartiality.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail George.Wilkins@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2025, to receive the latest updates and for any further details, please e-mail Natalia.Kay@citeline.com

More from Generics

Medicines For Europe Sets Out Trade Priorities

 
• By 

As Medicines for Europe gears up for a pair of conferences in Brussels next week, the organization has set out trade policy recommendations to strengthen access to medicines and the competitiveness of EU manufacturing, in a seminar with representatives from the European Commission and member states.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By 

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By 

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

 
• By 

In an exclusive interview, Meitheal Pharmaceuticals CEO Tom Shea discusses the company’s oncology strategy following the recent launch of generic Abraxane, alongside discussion of complex injectables, the biosimilars pipeline, and how $300m in backing is fueling the company's next phase of growth.

More from Business

Teva Continues Push Beyond Generics in Fosun Immunotherapy Tie-Up

 
• By 

Teva has agreed to partner with China’s Fosun Pharma to develop TEV-56278, a targeted cancer immunotherapy, marking the next step in its continued pivot from its generics roots toward complex biologics and innovative oncology treatments. The deal covers key Asian markets, including mainland China, w

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

‘I Saw An Unpolished Diamond’: Iconovo CEO Wäborg On Breaking Even In 2027 And Beyond

 
• By 

In an exclusive interview, Iconovo CEO Johan Wäborg outlines the company’s strategy to become a leader in dry powder inhalation by focusing on platform development, reformulated therapies, and B2B licensing, with a plan to break even by 2027.